Clinical trials: Neoplasms, Oral
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Advanced Solid Tumor Cancers, Medulloblastoma
An East Asian Study of LDE225
The purpose of this study is to determine Maximum Tolerated Dose (MTD) or recommended phase II dose of LDE225 when administered orally to two adult patient groups of East Asian (i.e., Japanese and Chinese/Taiwanese) with advanced…
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT01208831
- Testing
- LDE225
- Where
- 4 sites in Hong Kong, Japan and 1 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in advanced hematologic malignancies that harbor an IDH1 and/or IDH2 mutation
- Conditions
- Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematologic Malignancies
- Trial name
- NCT02492737
- Testing
- AG881
- Where
- 6 sites in United States, France
- Volunteers
- 46 people
- Sponsor
- Agios Pharmaceuticals, Inc.
Oral Pain, Oral Ulcers
Ethnopharmacological Studies in Oral Medicine
These are ethnomedicine studies of plants used by rural and indigenous peoples for pain and oral inflammation relief.
- Conditions
- Oral Pain, Oral Ulcers, Oral Tumors
- Trial name
- NCT00200837
- Where
- 3 sites in United States, Colombia and 1 more
- Volunteers
- 1,000 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Neoplasms, Lymphoma, Malignant
Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma
This is a first-in-man, open-label, non-randomized, multiple dose, multiple cycle, dose escalation study to determine the MTD, safety, PK, and pharmacodynamics of E7820 in patients with a malignant solid tumor or lymphoma.
- Trial name
- NCT00078637
- Testing
- E7820
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Eisai Inc.
Head and Neck Cancer
Analysis of Tumor Tissue and Lymph Nodes Surgically Removed From Patients With Cancers of the Head and Neck
RATIONALE: Diagnostic procedures, such as analysis of tumor tissue and lymph nodes that have been surgically removed, may improve the treatment of patients with cancers of the head and neck.
- Trial name
- NCT00002695
- Testing
- DNA stability analysis, microsatellite instability analysis, mutation analysis
- Where
- 4 sites in United States
- Volunteers
- 530 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Osteoradionecrosis, Radiotherapy
Risk Factors of Jaw Osteoradionecrosis in Oral Cavity Cancer Patients Post-Radiotherapy
Osteoradionecrosis (ORN) of the jaw is a serious complication that can occur after radiation therapy for head and neck cancers, including oral cavity cancer (OCC).
- Conditions
- Osteoradionecrosis, Radiotherapy, Risk Factors, Oral Cancer
- Trial name
- AOITC (NCT07836829)
- Volunteers
- 1,000 people
- Sponsor
- AO Innovation Translation Center
Rectal Cancer
Exploring the Predictive Effect of Intestinal and Oral Microbiota on the Efficacy of Neoadjuvant Radiotherapy and Chemotherapy for Locally Advanced Rectal Cancer Based on Machine Learning
This study is a one-year, observational, prospective cohort study. For enrolled patients with newly diagnosed locally advanced rectal cancer, the treatment plan will be decided by the physician based on the 2022 NCCN Rectal…
- Trial name
- NCT07346729
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer).
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01604772
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Oral Cancer
Personalized Survivor Care Plan for Oral Cancer Patients-Effects on Physical-Psychological Functions and Return-to-Work
Background: Due to the complex treatment modalities and long-term side effects, oral cancer (OC) patients might suffer from psychological and physical distress and be unable to return to work (RTW).
- Trial name
- NCT04214912
- Testing
- Personalized Survivor Care Plan (PSCP)
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Oral Anticancer Therapy.
Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events
The improvement of the care pathway of oncology patients through Clinical Pharmacy activities for outpatients (such as pharmaceutical consultation) should be implemented and evaluated.
- Trial name
- PharmaOnco (NCT02733965)
- Testing
- Pharmaceutical Consultations, No Pharmaceutical Consultations
- Where
- France
- Volunteers
- 190 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer
Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
This phase II trial is studying how well bortezomib followed by doxorubicin at the time of disease progression works in treating patients with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (cancer) of the…
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00077428
- Testing
- bortezomib, doxorubicin hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Squamous Cell Carcinoma
Pembrolizumab in Combination With CRT for LA-SCCHN
This is a single-arm, multi-site, open-label trial of pembrolizumab (MK-3475) used in combination with standard, cisplatin-based, definitive chemoradiotherapy (CRT) in patients with stage III-IVB squamous cell carcinoma of the…
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT02586207
- Testing
- pembrolizumab (MK-3475), Cisplatin, Radiation
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sanford Health
Breast Cancer
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Primary Objectives: Dose Escalation: To assess the incidence rate of dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) as well as the recommended dose (RD) of amcenestrant administered as monotherapy…
- Trial name
- AMEERA-1 (NCT03284957)
- Testing
- Amcenestrant, Palbociclib, Alpelisib
- Where
- 25 sites in United States, Belgium and 8 more
- Volunteers
- 136 people
- Sponsor
- Sanofi
Leukemia, Myeloid, Acute
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
This is a 2-part, open-label, interventional study conducted in approximately 42 subjects with AML harboring an IDH2 mutation. The overall study is a 3-arm investigation of the PK effects of enasidenib at steady state on the…
- Trial name
- NCT03720366
- Testing
- enasidenib, Arm 1 probes, Arm 2 Probes
- Where
- 10 sites in Australia, South Korea
- Volunteers
- 40 people
- Sponsor
- Celgene
Periodontal Disease, Gingivitis and Periodontal Diseases
Hippo Signaling Pathway Proteins in Gingival Crevicular Fluid of Individuals With Periodontal Disease
Periodontal disease is a chronic inflammatory condition of the tooth-supporting tissues in which the host inflammatory response drives the destruction of alveolar bone and periodontal attachment.
- Conditions
- Periodontal Disease, Gingivitis and Periodontal Diseases, Biomarker Discovery and Validation, Pathways
- Trial name
- BYHN-GCF-HIPPO (NCT07759466)
- Testing
- ELISA Biomarker Analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Inonu University
Neoplasms, Breast
A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer
This study will characterize the effect of elevated gastric pH mediated by the proton-pump inhibitor, esomeprazole, on the relative bioavailability of lapatinib in subjects with metastatic ErbB2 positive breast cancer.
- Trial name
- NCT00849329
- Testing
- lapatinib, lapatinib plus esomeprazole
- Where
- 4 sites in United States, South Korea and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline